GlycoMimetics Inc. (NASDAQ:GLYC) has been assigned a consensus recommendation of “Buy” from the six research firms that are presently covering the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $14.33.
A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity reissued a “buy” rating and set a $12.00 price objective on shares of GlycoMimetics in a research report on Sunday, August 7th. Stifel Nicolaus boosted their price objective on shares of GlycoMimetics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research downgraded shares of GlycoMimetics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. Jefferies Group reissued a “buy” rating on shares of GlycoMimetics in a research report on Friday, August 5th. Finally, Cowen and Company began coverage on shares of GlycoMimetics in a research note on Monday, August 15th. They set an “outperform” rating on the stock.
Shares of GlycoMimetics (NASDAQ:GLYC) traded up 2.33% on Friday, hitting $6.60. The stock had a trading volume of 7,772 shares. The company has a 50 day moving average price of $6.29 and a 200-day moving average price of $7.20. The stock’s market cap is $152.23 million. GlycoMimetics has a 12 month low of $3.70 and a 12 month high of $9.25.
GlycoMimetics (NASDAQ:GLYC) last issued its quarterly earnings data on Friday, November 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.10. On average, equities research analysts anticipate that GlycoMimetics will post ($1.58) earnings per share for the current year.
In other GlycoMimetics news, VP Helen M. Thackray sold 4,000 shares of the business’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $7.00, for a total value of $28,000.00. Following the sale, the vice president now owns 156,715 shares in the company, valued at approximately $1,097,005. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 52.50% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the company. Teachers Advisors LLC boosted its stake in shares of GlycoMimetics by 32.6% in the third quarter. Teachers Advisors LLC now owns 14,375 shares of the company’s stock valued at $103,000 after buying an additional 3,534 shares during the last quarter. Barclays PLC boosted its stake in shares of GlycoMimetics by 77.1% in the second quarter. Barclays PLC now owns 15,816 shares of the company’s stock valued at $115,000 after buying an additional 6,885 shares during the last quarter. Strs Ohio bought a new stake in shares of GlycoMimetics during the second quarter valued at approximately $115,000. Schwab Charles Investment Management Inc. bought a new stake in shares of GlycoMimetics during the second quarter valued at approximately $143,000. Finally, TFS Capital LLC bought a new stake in shares of GlycoMimetics during the second quarter valued at approximately $149,000. Institutional investors and hedge funds own 80.29% of the company’s stock.